Novel neoadjuvant therapy paradigms for bladder cancer: Results from the National Cancer Center Institute Forum
| Autor: | Seth P. Lerner, Susan Groshen, Robert Dreicer, Emanuel F. Petricoin, Fred Waldman, Dean F. Bajorin, Donna E. Hansel, William U. Shipley, David J. McConkey, Michael P. Hagan, Colin P.N. Dinney, Dan Theodorescu, Andrew M. Hruszkewycz, Lawrence D. True, Bogdan Czerniak |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Urologic Diseases
Oncology medicine.medical_specialty Urology medicine.medical_treatment Clinical Trials and Supportive Activities Oncology and Carcinogenesis Neoadjuvant chemotherapy Article Targeted therapy 6.9 Resources and infrastructure (treatment evaluation) Clinical Research Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Adjuvant Neoadjuvant therapy Cancer Clinical Trials as Topic Radiation Bladder cancer business.industry Evaluation of treatments and therapeutic interventions Chemoradiotherapy Chemoradiotherapy Adjuvant Urology & Nephrology medicine.disease National Cancer Institute (U.S.) Neoadjuvant Therapy United States Gemcitabine Surgery Clinical trial Urinary Bladder Neoplasms Biomarker (medicine) Translational science business medicine.drug |
| Zdroj: | Urologic oncology, vol 32, iss 8 |
| ISSN: | 1078-1439 |
| DOI: | 10.1016/j.urolonc.2013.10.021 |
| Popis: | Although bladder cancer (BC) is a significant health threat to the US population, integrated clinical and laboratory investigations of this disease lag behind those of other types of cancer. Advances in BC are especially challenged due in part to a general decreased level of funding over the past 5 years. It is ironic that despite the awareness that BC is the 5th most commonly diagnosed solid malignancy in the United States, and one of the most costly to treat, funding for this organ site lags far behind that of other less common malignancies. Moreover, BC offers several unique opportunities for translational research that make it an ideal candidate for investigation. One distinct advantage over other solid tumor sites is that urine and tissue are readily available for translational studies that can direct the development of novel therapy for this disease. The NCI sponsored “Novel Neoadjuvant Therapy for Bladder Cancer” forum held in brought leading clinical and laboratory-based scientists together with the advocacy community to lay the groundwork for collaborative discovery and translation. The goal of the meeting was to bridge the gaps in translational science and develop the concepts for two novel biomarker-driven clinical trials, one in the neoadjuvant presurgical setting and the other in the setting of bladder preservation with chemoradiation. The meeting provided a unique opportunity to launch a collective effort to establish molecular-based therapy for UC. Herein, we summarize the proceedings of this meeting, and the future plans resulting from this forum. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect